http://142-54-23-223.fusionmedialtd.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 03 Jul 2026 18:10:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://142-54-23-223.fusionmedialtd.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html <p align="justify">HALIFAX, Nova Scotia, July 03, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases today announced that it has received a Notice of Termination for Convenience from the National Institute of Allergy and Infectious Diseases (“NIAID”), part of the National Institutes of Health (“NIH”), in connection with the Company’s contract supporting development of the VXV-01 fungal vaccine candidate.</p> <p align="justify">The notice relates to contract number 75N93025C00033, which was <a target="_blank" href="https://www.globenewswire.com/Tracker?data=OgQcfPZmU-Yi7EuibAhsUlrTcaHeVqOlFXUYJisydnVcvfjO5j6HnPDSE9fTKTXDwIdmKFy9tdFK7tspl8UQalk_3Wea98Z9LUNmOb1o8MJWYOc2ftXspeaJXJu-xfSJc-Z30FfxajHb41V_FBd1FHsgg3npSL5zuB-mrMVWwYv_vkjme3m-nJI9vsSSr9rSeP7RKuveY6TjHBUykC5TbN0zbYtz8T2cJzFuL_F4X63wj-EDUcu2GCFhAcmu6FyC1b76N2xYdUQpmA1PPruplSM4GP-Ijobnem45MZme4Kk9oG5p2u4J3tgcnyzFzXjt" rel="nofollow" target="_blank">awarded in October 2025</a>. The five<strong>–</strong>year contract consists http://www.streetinsider.com/Globe+Newswire/Appili+Therapeutics+Announces+Receipt+from+NIAID+of+a+Notice+of+Termination+for+Convenience+on+the+Contract+for+the+VXV-01+Program/26731065.html Fri, 03 Jul 2026 18:10:00 -0400 A.19655944 A.29922014 APLI APLIF O.03307993 O.40274338 O.42081221 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338 http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html <p><em>LIKMEZ® (ATI-1501) commercial momentum building in U.S. market</em><br/><br/><em>US$40 million NIAID award supporting VXV-01 advancement through Phase 1</em><br/></p> <p align="justify">HALIFAX, Nova Scotia, June 26, 2026 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced its financial and operational results for the fiscal year ended March 31, 2026 (“FYE 2026”), and provided an update on fiscal 2027. All figures are stated in Canadian dollars unless otherwise stated.</p> <p align="justify">&quot;Fiscal year 2026 marked a significant transition for Appili as http://www.streetinsider.com/Press+Releases/Appili+Therapeutics+Reports+Fiscal+Year+2026+Financial+and+Operational+Results/26700185.html Fri, 26 Jun 2026 18:29:00 -0400 A.01308211 A.06822034 A.13522767 A.19655944 APLI APLIF O.03289173 O.03307993 O.20026344 O.21107627 O.40274338